1
|
Liu X, Liu M, Cao B, Qiao J, Zhang X. Relationship between IDH1/2 and TERT promoter mutation and the prognosis of human glioma patients. Pak J Med Sci 2023; 39:843-847. [PMID: 37250582 PMCID: PMC10214788 DOI: 10.12669/pjms.39.3.7149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 09/20/2022] [Accepted: 01/27/2023] [Indexed: 11/02/2023] Open
Abstract
Objective To investigate the relationship between isocitrate dehydrogenase (IDH) 1/2 mutation, telomerase reverse transcriptase (TERT) gene promoter mutation and the prognosis of human glioma patients. Methods One hundred fifteen patients with human glioma, treated surgically in The First Affiliated Hospital of Hebei North University from January 2019 to January 2020, were included. All patients were followed up until January 31, 2022. The mutations of IDH1/2 and TERT promoter were analyzed, and risk factors affecting survival of the patients with glioma were assessed. Results IDH1 gene mutation occurred in 82 cases, IDH2 gene mutation occurred in five cases and TERT promoter mutation occurred in 54 cases. Univariate analysis showed that tumor WHO grade, resection range, preoperative Karnofsky performance status score, postoperative radiotherapy and chemotherapy, IDH1/2 gene and TERT promoter mutation influenced postoperative survival of patients with glioma (P<0.05). Kaplan-Meier survival curve showed that IDH1/2 gene and TERT promoter mutation were significantly different from those of wild-type patients (P<0.05). Conclusion IDH1/2 gene and TERT promoter mutations are more frequent in patients with human glioma. These related factors can be used as molecular markers to aid in the prognosis of patients with glioma.
Collapse
Affiliation(s)
- Xipeng Liu
- Xiping Liu, Department of Neurosurgery, The First Affiliated Hospital of Hebei North University Zhangjiakou 075000, Hebei Province, P.R. China
| | - Ming Liu
- Ming Liu, Department of Neurosurgery, The First Affiliated Hospital of Hebei North University Zhangjiakou 075000, Hebei Province, P.R. China
| | - Bing Cao
- Bing Caom, Department of Neurosurgery, The First Affiliated Hospital of Hebei North University Zhangjiakou 075000, Hebei Province, P.R. China
| | - Jianxin Qiao
- Jianxin Qiao, Department of Neurosurgery, The First Affiliated Hospital of Hebei North University Zhangjiakou 075000, Hebei Province, P.R. China
| | - Xiufeng Zhang
- Xiufeng Zhang, Department of Neurosurgery, The First Affiliated Hospital of Hebei North University Zhangjiakou 075000, Hebei Province, P.R. China
| |
Collapse
|
2
|
Liu Z, Yang Z, He L. Effect of miR‑29a‑3p in exosomes on glioma cells by regulating the PI3K/AKT/HIF‑1α pathway. Mol Med Rep 2023; 27:72. [PMID: 36799154 PMCID: PMC9942261 DOI: 10.3892/mmr.2023.12959] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 01/16/2023] [Indexed: 02/12/2023] Open
Abstract
Exosomes secreted by glioma cells can carry a number of bioactive molecules. As the most abundant noncoding RNA in exosomes, microRNAs (miRNAs) are involved in signaling between tumor cells in a number of ways. In addition, hypoxia is an important feature of the microenvironment of most tumors. The present study investigated the effect of miR‑29a‑3p in glioma exosomes on the proliferation and apoptosis levels of U251 glioma cells under hypoxia. Qualitative PCR results showed that the expression level of miR‑29a‑3p in plasma exosomes of glioma patients was lower than that of normal subjects. By conducting hypoxia experiments in vitro on U251 glioma cells, it was found that the expression level of miR‑29a‑3p decreased following hypoxia, while overexpression of miR‑29a‑3p significantly decreased the proliferation of U251 glioma cells and promoted apoptosis by inhibiting the expression of the antiapoptotic marker Bcl‑2 and increasing the expression of the proapoptotic marker Bax The potential targets of miR‑29a‑3p were predicted by online tools and validated by a dual‑luciferase gene reporter assay. miR‑29a‑3p was found to target and regulate PI3K, which in turn inhibited the activity of the PI3K‑AKT pathway, thereby reducing the expression of hypoxia inducible factor (HIF)‑1α protein. Furthermore, the effects of miR‑29a‑3p on proliferation and apoptosis in glioma cells in those processes could be reversed by the PI3K‑AKT agonist Recilisib. In addition, the inhibitory effect of miR‑29a‑3p on the PI3K/AKT/HIF‑1α regulatory axis could cause a decrease in the expression levels of pyruvate dehydrogenase kinase‑1 and pyruvate dehydrogenase kinase‑2 and eventually lead to a reduction in glycolysis in U251 glioma cells. Similarly, Recilisib slowed the inhibitory effect of miR‑29a‑3p on glycolysis and glycolysis‑related molecules. The results of this study tentatively confirm that miR‑29a‑3p carried by exosomes can be used as a novel diagnostic marker and a potential inhibitory molecule for glioma cells, providing a new theoretical and experimental basis for the precise clinical treatment of glioma.
Collapse
Affiliation(s)
- Zeqiang Liu
- Department of Laboratory Medicine, Peking University Third Hospital, Beijing 100191, P.R. China,Correspondence to: Dr Zeqiang Liu, Department of Laboratory Medicine, Peking University Third Hospital, 49 Huayuan North Road, Beijing 100191, P.R. China, E-mail:
| | - Zheng Yang
- Department of Neurosurgery, The First People's Hospital of Jiashan, Jiaxing, Zhejiang 314100, P.R. China
| | - Lu He
- Department of Laboratory Medicine, Peking University Third Hospital, Beijing 100191, P.R. China
| |
Collapse
|
3
|
van Heerden J, Balagadde-Kambugu J, Angom R, Lusobya RC, Chantada G, Desjardins L, Fabian ID, Israels T, Paintsil V, Hessissen L, Diouf MN, Elayadi M, Turner SD, Kouya F, Geel JA. Evaluating the baseline survival outcomes of the "six Global Initiative for Childhood Cancer index cancers" in Africa. Pediatr Hematol Oncol 2022; 40:203-223. [PMID: 36369884 DOI: 10.1080/08880018.2022.2140860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Limited survival data for the six Global Initiative for Childhood Cancer (GICC) priority cancers are available in Africa. Management of pediatric malignancies in Africa is challenging due to lack of resources, setting-specific comorbidities, high rates of late presentation and treatment abandonment. Reporting of outcome data is problematic due to the lack of registries. With the aim of evaluating the feasibility of baseline outcomes for the six index cancers, we present a descriptive analysis of respective survival rates in Africa. The survival rates were between 18% (lower middle-income countries) to 82.3% (upper middle-income countries) for acute lymphoblastic leukemia, between 26.9% (low-income countries) to 77.9% (upper middle-income countries) for nephroblastoma, between 23% (low-income countries) to 100% (upper middle-income countries), for retinoblastoma, 45% (low-income countries) to 95% (upper middle-income countries) for Hodgkin lymphoma and 28% (low-income countries) to 76% (upper middle-income countries) for Burkitt lymphoma. Solutions to improve survival rates and reported outcomes include establishing and funding sustainable registries, training and to actively include all countries in consortia from different African regions.HighlightsContinental differences in childhood cancer management such lack of resources, setting-specific comorbidities, high rates of late presentation and treatment abandonment, present challenges to the achievement of Global Initiative for Childhood Cancer goals.The available data registries do not adequately inform on the true incidences and outcomes of childhood cancers in Africa.The pathophysiology of some childhood cancers in Africa are associated with high-risk prognostic factors.Outcomes can be improved by greater regional collaboration to manage childhood cancer based on local resources and tumor characteristics.Some individual countries have reached the Global Initiative for Childhood Cancer goals for single cancers and it should be possible for more African countries to follow suit.
Collapse
Affiliation(s)
- Jaques van Heerden
- Pediatric Hematology and Oncology, Department of Pediatrics, Antwerp University Hospital, Antwerp, Belgium.,Pediatric hematology and Oncology, Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa.,Department of Pediatric Oncology, Uganda Cancer Institute, Kampala, Uganda
| | | | - Racheal Angom
- Department of Pediatric Oncology, Uganda Cancer Institute, Kampala, Uganda
| | - Rebecca Claire Lusobya
- Department of Ophthalmology, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda
| | - Guillermo Chantada
- Department of Pediatric Oncology, Hospital Sant Joan de Deu, Barcelona, Spain
| | | | - Ido Didi Fabian
- Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Tel-Aviv University, Tel-Aviv, Israel.,International Center for Eye Health London School of Hygiene and Tropical Medicine, London, UK
| | - Trijn Israels
- Department of Pediatrics, Queen Elizabeth Central Hospital, Kamuzu University of Health Sciences, Blantyre, Malawi
| | - Vivian Paintsil
- Department of Child Health, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Laila Hessissen
- Pediatric Hematology and Oncology Center, University Mohammed V Rabat, Rabat, Morocco
| | | | - Moatasem Elayadi
- Department of Pediatric Oncology, National Cancer Institute, Egypt & Children Cancer Hospital of Egypt (CCHE-57357), Cairo University, Giza, Egypt
| | | | - Francine Kouya
- Department of Pediatric Oncology, Cameroon Baptist Convention Hospitals in Mutengene, Mbingo and Banso, Mutengene, Cameroon
| | - Jennifer A Geel
- Division of Pediatric Hematology-Oncology, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Witwatersrand, South Africa
| |
Collapse
|
4
|
Li Q, Zhang L, Chen C, Gan Y, Jiang L, Li S, Xiang W, Ming Y, Yang C, Zhou J. Caregiver burden and influencing factors among family caregivers of patients with glioma: A cross-sectional survey. J Clin Neurosci 2021; 96:107-113. [PMID: 34840093 DOI: 10.1016/j.jocn.2021.11.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 11/12/2021] [Accepted: 11/13/2021] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The main responsibility of caring for patients with glioma is assumed by family caregivers who experience a considerable burden during the care process. This study aimed to investigate the level of caregiver burden and explore its associated factors among family caregivers of patients with glioma. METHODS We conducted a cross-sectional study among 131 family caregivers of glioma patients from October 2017 to November 2019. We used the following measurement tools: a demographic questionnaire, the Zarit Burden interview (ZBI), the Hamilton anxiety and depression scale, and the family APGAR index. We used multiple linear regression analysis to determine the factors related to caregiver burden. RESULTS The ZBI score for the family caregivers of glioma patients was 31.29 (SD = 13.54), and most caregivers (71.7%) reported moderate and severe caregiver burdens. Caregivers' daily sleep time and anxiety symptoms and patients' depressive symptoms independently predicted caregiver burden. CONCLUSIONS Family caregivers of glioma patients experienced a moderate burden. Personalised psychological intervention and sleep health guidance for patients and caregivers should be considered to reduce family caregiver burden and enhance the quality of life and mental health of both patients and their caregivers.
Collapse
Affiliation(s)
- Qianqian Li
- School of Nursing, Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China
| | - Liying Zhang
- School of Nursing, Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China
| | - Chaoyi Chen
- Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Chunhui Road 16#, Lu Zhou 646000, China
| | - Yajie Gan
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Sichuan Clinical Research Center for Neurosurgery, Taiping Street 25#, Lu Zhou 646000, China; Academician (Expert) Workstation of Sichuan Province, Taiping Street 25#, Lu Zhou 646000, China; Laboratory of Neurosurgery Diseases and Brain Function, Taiping Street 25#, Lu Zhou 646000, China
| | - Lin Jiang
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Sichuan Clinical Research Center for Neurosurgery, Taiping Street 25#, Lu Zhou 646000, China; Academician (Expert) Workstation of Sichuan Province, Taiping Street 25#, Lu Zhou 646000, China; Laboratory of Neurosurgery Diseases and Brain Function, Taiping Street 25#, Lu Zhou 646000, China
| | - Shenjie Li
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Sichuan Clinical Research Center for Neurosurgery, Taiping Street 25#, Lu Zhou 646000, China; Academician (Expert) Workstation of Sichuan Province, Taiping Street 25#, Lu Zhou 646000, China; Laboratory of Neurosurgery Diseases and Brain Function, Taiping Street 25#, Lu Zhou 646000, China
| | - Wei Xiang
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Sichuan Clinical Research Center for Neurosurgery, Taiping Street 25#, Lu Zhou 646000, China; Academician (Expert) Workstation of Sichuan Province, Taiping Street 25#, Lu Zhou 646000, China; Laboratory of Neurosurgery Diseases and Brain Function, Taiping Street 25#, Lu Zhou 646000, China
| | - Yang Ming
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Sichuan Clinical Research Center for Neurosurgery, Taiping Street 25#, Lu Zhou 646000, China; Academician (Expert) Workstation of Sichuan Province, Taiping Street 25#, Lu Zhou 646000, China; Laboratory of Neurosurgery Diseases and Brain Function, Taiping Street 25#, Lu Zhou 646000, China
| | - Changmei Yang
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Sichuan Clinical Research Center for Neurosurgery, Taiping Street 25#, Lu Zhou 646000, China; Academician (Expert) Workstation of Sichuan Province, Taiping Street 25#, Lu Zhou 646000, China; Laboratory of Neurosurgery Diseases and Brain Function, Taiping Street 25#, Lu Zhou 646000, China.
| | - Jie Zhou
- Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Taiping Street 25#, Lu Zhou 646000, China; Sichuan Clinical Research Center for Neurosurgery, Taiping Street 25#, Lu Zhou 646000, China; Academician (Expert) Workstation of Sichuan Province, Taiping Street 25#, Lu Zhou 646000, China; Laboratory of Neurosurgery Diseases and Brain Function, Taiping Street 25#, Lu Zhou 646000, China.
| |
Collapse
|